Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

Results Reported From Three NCI-Sponsored Clinical Trials

SOUTH SAN FRANCISCO, CA June 28, 2007 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced results from the analyses of three Phase II clinical trials of ispinesib administered as monotherapy, one in patients with hepatocellular cancer, one in patients with melanoma, and one in patients with hormone-refractory prostate cancer. Ispinesib is a novel small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division. Ispinesib has arisen from a broad strategic collaboration between Cytokinetics and GlaxoSmithKline (GSK) to discover, develop and commercialize novel small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. All three clinical trials were sponsored by the National Cancer Institute (NCI).

A Phase II clinical trial designed to evaluate the safety and efficacy of ispinesib in the treatment of patients with locally advanced, recurrent or metastatic hepatocellular cancer was recently completed. In Stage 1 of this two-stage clinical trial, 15 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. This trial was designed to require at least 1 confirmed partial or complete response out of 15 evaluable patients in Stage 1 in order to proceed to Stage 2. The best overall response was stable disease seen in 7 of the 15 patients treated. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the second stage and therefore recruitment to Stage 2 was not opened. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscript is being prepared.

A Phase
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:8/29/2014)...  A Boston Scientific Corporation (NYSE: ... and preliminary long term stricture resolution of benign ... issue of the peer-reviewed journal, Gastroenterology. ... conducted in 11 countries and five continents, and ... (FCSEMS) after extended indwell (i.e., up to 12 ...
(Date:8/29/2014)... , Aug. 29, 2014 Thoratec Corporation ... device-based mechanical circulatory support therapies to save, support and ... in the 2014 Morgan Stanley Global Healthcare Conference on ... , President and Chief Executive Officer, will provide an ... Daylight Time (9:55 a.m., Pacific Daylight Time).   ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Peptide Cancer Therapeutics Market & Pipeline Insight ... The conventional methods developed to prevent and eradicate the ... treatment. These methods are confined to low specificity, safety ... researchers to look for a better solution. It has ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
... Sept. 23, 2011 A pharmaceutical company,s marketing strategy ... introducing a new brand in a space where the ... two-thirds of companies, the most frequent changes require shifting ... activities, such as professional relations, promotional literature, sampling, and ...
... 2011 Watson Pharmaceuticals, Inc. (NYSE: WPI ), ... Company intends to release its third quarter 2011 financial results ... the U.S. financial markets.  The Company will also host a ... November 1, 2011 to discuss its financial results and provide ...
Cached Medicine Technology:Pharmaceutical Marketing Strategy Balances Support Between New & Established Products in the Same Indication 2Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings 2
(Date:8/30/2014)... Jake W., 18, is completing his high ... Back2Basics Outdoor Adventures transition program known as Beyond the ... I can actually start on a real career path,” said ... done.” , He has six months of sobriety under his ... choose to continue on to the Beyond the Basics transition ...
(Date:8/30/2014)... 2014 “In 2013, a vehicle crash occurred ... says in a recently released article on 2013 Washington ... in an auto accident every 12 minutes, and a motorcyclist ... “Based on the 2013 statistics, between now and this same ... The threat of an auto accident is real and impending ...
(Date:8/30/2014)... FL (PRWEB) August 30, 2014 Zensah®, the ... Camo Compression Leg Sleeve . The camo sleeves are ... Leg Sleeve collection. The camo line includes classic colors ... and magenta. , Known as tibial stress syndrome, shin ... of the lower leg. Swollen and irritated muscles, stress fractures, ...
(Date:8/30/2014)... Barton Associates, an industry leading physician, ... , announces a new office location in Keene, NH, ... headquartered in Peabody, MA, with additional staffing centers in ... Jupiter, FL. , Barton Associates made the decision to ... crisis affecting the United States, a crisis that will ...
(Date:8/30/2014)... August 30, 2014 What challenges exist ... are the latest trends, concerns, and considerations? Sports ... Ken Pendleton recently spoke with Woody Wommack, Southeast Football ... current issues in football recruiting. Notably, Wommack spoke ... athletes, changes that he thinks are coming as a ...
Breaking Medicine News(10 mins):Health News:Startling Washington Auto Accident Statistics Discussed In Recently Released Article By The Jones Firm 2Health News:Camo Compression Leg Sleeves Provide Shin Splint Relief for Runners 2Health News:Barton Associates to Open a New Office Location in Keene, NH 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 3
... Now Available on Online Community to Facilitate Collaboration ... BEACH, Fla., May 8 With a growing ... short weeks since launch, e-Zassi.com has added an ... participants involved in the discovery, development and commercialization ...
... York City Raises Money for STAR (TM) ... Charcot-Marie-Tooth Association,s second annual "Honor a Star. Be a Star." ... achievement raised a record amount of over $350,000 at the ... Proceeds earned from event sponsorship, ticket sales and auction items ...
... One Global Health Threat"WASHINGTON, May 8 Today, HIV ... of Human Virology at the University of Maryland ... of the World Foundation for AIDS Research and Prevention, ... six objectives to end the HIV/AIDS pandemic. They ...
... -- Mindray Medical,International Limited (NYSE: MR ... devices worldwide announced today it filed with the,Securities ... 20-F that included,audited financial statements for the year ... Annual Report on Form 20-F is available online,at ...
... part of the Elekta Group, has been selected to ... the 2009 American Society of Clinical Oncology,s (ASCO) Annual ... County Convention Center, in Orlando, Florida. Chosen according to ... third consecutive year Impac Software ...
... May 8, 2009 AMERIGROUP Corporation (NYSE: ... the Deutsche Bank 34th Annual Healthcare Conference on May 18 ... Monday, May 18 at 2:25pm Eastern Time, can be accessed ... the investors, page. A replay will be available for 30 ...
Cached Medicine News:Health News:New Advanced Search and Matching Function Drives e-Zassi.com's Enhanced Functionality 2Health News:Charcot-Marie-Tooth Association's 'Honor a Star. Be a Star.' Gala Generates Over $350,000 for CMT Research 2Health News:A Global Call to Action From HIV Co-Discoverers Robert Gallo and Luc Montagnier 2Health News:A Global Call to Action From HIV Co-Discoverers Robert Gallo and Luc Montagnier 3Health News:Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission 2Health News:Impac Software Selected to Present at the Electronic Health Records Lab During 2009 ASCO Annual Meeting 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: